LCTX

Business Context and Reporting Period

This summary covers the Quarterly Report on Form 10-Q for BioTime, Inc. (Note: The input metadata referenced "Lineage Cell Therapeutics," but the filing text explicitly identifies the registrant as BioTime, Inc.) for the period ended March 31, 2010. BioTime is a biotechnology company operating in two primary segments: blood plasma volume expanders (led by the product Hextend) and regenerative medicine (focusing on human embryonic stem cells and induced pluripotent stem cells). The company markets research products through its subsidiary Embryome Sciences and is developing therapeutic applications through OncoCyte Corporation and BioTime Asia, Limited.

Key Financial Metrics

Note: The filing does not provide explicit gross margin or operating margin percentages. The company reported no debt obligations as of March 31, 2010, having paid off lines of credit in the prior year.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 158% to $767,127 from $296,743. This was driven primarily by a $395,096 grant income from the California Institute of Regenerative Medicine (CIRM) and a 33% increase in royalty revenues from Hextend sales ($297,000 vs. $222,667).
• Expense Increases: Operating expenses rose significantly to $2,093,249 from $1,207,998. Research and Development (R&D) expenses more than doubled to $1,159,951 due to increased salaries, consulting fees, and stock-based compensation. General and Administrative (G&A) expenses increased to $933,298, largely due to higher legal fees and director compensation.
• Interest Expense: Interest expense dropped dramatically to $58 from $608,027, reflecting the full repayment of borrowings under lines of credit in 2009.
• Cash Position: Cash and cash equivalents increased substantially to $11.17 million from $541,106 in the prior year, bolstered by financing activities (warrant and option exercises) and the CIRM grant.

Outlook, Risks, and Unusual Items

• Subsequent Event (Acquisition): On May 3, 2010, BioTime completed the acquisition of ES Cell International Pte Ltd (ESI) for approximately $35 million in principal and accrued interest, paid via the issuance of 1,383,400 common shares and warrants. This acquisition aims to leverage ESI's clinical-grade stem cell lines.
• Revenue Recognition Timing: Royalty revenues are recognized in the quarter reports are received, not when sales occur. Royalties from Q1 2010 sales will be recognized in Q2 2010.
• Liquidity and Capital Needs: While cash reserves are currently strong ($11.17M), the company notes it may need additional debt or equity capital to fund operations and clinical trials. Future revenues depend heavily on Hextend royalties and the CIRM grant.
• Warrant Expiration: Approximately 12.1 million warrants are outstanding, expiring in Q4 2010. Management plans to offer a discount on the exercise price to encourage early exercise.
• Risks: Key risks include the uncertainty of clinical trial results, regulatory approvals (FDA), competition, and the ability to secure additional financing. The company has substantial net operating loss carryovers and a 100% valuation allowance on deferred taxes.

Investor Verification Checklist

• Verify the impact of the May 3, 2010 acquisition of ESI on future cash burn and dilution, as this occurred after the reporting period.
• Monitor the timing of royalty payments from Hospira and CJ CheilJedang, as revenue recognition is lagged by 90 days post-quarter.
• Assess the sustainability of the CIRM grant ($395k/quarter) as a primary revenue source and the timeline for commercialization of stem cell research products via Millipore.
• Review the status of the warrant discount offer intended to raise capital before the Q4 2010 expiration.
• Confirm the progress of clinical trials for therapeutic products (OncoCyte and BioTime Asia), which are currently in early preclinical stages.